These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

840 related items for PubMed ID: 23382539

  • 1. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M, Grobbee DE, Bots ML, Thom S, Webster R, Rodgers A, Visseren FL, Spiering W.
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [Abstract] [Full Text] [Related]

  • 2. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, Neal B, Hillis GS, Rafter N, Tonkin A, Webster R, Billot L, Bompoint S, Burch C, Burke H, Hayman N, Molanus B, Reid CM, Shiel L, Togni S, Rodgers A, Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration.
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [Abstract] [Full Text] [Related]

  • 3. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M, Spiering W, Visseren FL, Grobbee DE, Bots ML, Stanton A, Patel A, Prabhakaran D, Webster R, Thom S, Rodgers A, UMPIRE investigators.
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [Abstract] [Full Text] [Related]

  • 4. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial.
    Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A, Visseren FL, Bots ML, Spiering W.
    Int J Cardiol; 2015 Feb 15; 181():193-9. PubMed ID: 25528311
    [Abstract] [Full Text] [Related]

  • 5. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M, Webster R, Visseren FLj, Bots ML, Grobbee DE, Spiering W, Rodgers A, Programme to Improve Life and Longevity (PILL) Collaborative Group.
    Eur J Prev Cardiol; 2016 Aug 15; 23(12):1289-97. PubMed ID: 26743587
    [Abstract] [Full Text] [Related]

  • 6. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S, Field J, Poulter N, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Rodgers A.
    Eur J Prev Cardiol; 2014 Feb 15; 21(2):252-61. PubMed ID: 23038750
    [Abstract] [Full Text] [Related]

  • 7. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
    Yusuf S, Pais P, Sigamani A, Xavier D, Afzal R, Gao P, Teo KK.
    Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):463-71. PubMed ID: 22787067
    [Abstract] [Full Text] [Related]

  • 8. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
    Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD.
    Trials; 2011 Jan 05; 12():3. PubMed ID: 21205325
    [Abstract] [Full Text] [Related]

  • 9. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS, Kim SH, Kim JK, Ko SH, Ko JE, Park SJ, Park MG, Lee JH, Hyon MS.
    Ann Pharmacother; 2011 Jul 05; 45(7-8):841-9. PubMed ID: 21693699
    [Abstract] [Full Text] [Related]

  • 10. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A.
    BMJ; 2014 May 27; 348():g3318. PubMed ID: 24868083
    [Abstract] [Full Text] [Related]

  • 11. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
    Truelove M, Patel A, Bompoint S, Brown A, Cass A, Hillis GS, Peiris D, Rafter N, Reid CM, Rodgers A, Tonkin A, Usherwood T, Webster R, Kanyini GAP Collaboration.
    Cardiovasc Ther; 2015 Dec 27; 33(6):347-52. PubMed ID: 26280247
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Ferket BS, Hunink MG, Khanji M, Agarwal I, Fleischmann KE, Petersen SE.
    Heart; 2017 Apr 27; 103(7):483-491. PubMed ID: 28077465
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.